Clinical practice guidelines for the use of erythroid-stimulating agents: ASCO, EORTC, NCCN

Cancer Treatment and Research

Volumn 157, Issue , 2011, Pages 239-248

  Lichtin, Alan E ^a,b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; IRON; IRON DEXTRAN; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ANEMIA; BLOOD TRANSFUSION; CANCER PATIENT; CLINICAL PRACTICE; DIET SUPPLEMENTATION; DRUG INDICATION; DRUG USE; EUROPE; FOOD AND DRUG ADMINISTRATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT INDICATION; UNITED STATES; VENOUS THROMBOEMBOLISM;

ANEMIA; CLINICAL TRIALS AS TOPIC; HEMATINICS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; THROMBOSIS;

EID: 78349288428     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7073-2_14     Document Type: Review

References (28)

1. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083-107.
2. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26(1):132-49.
3. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Sonbeyran P. European Organization for Research and Treatment of Cancer [EORTC] guidelines for the use of erythropoietin proteins in anaemic patients with cancer; 2006 update. Eur J Cancer. 2007;43(2):258-70. [E pub 2006 Dec 19].
4. Rodgers GM, Becker PS, Bennett CL, Cella D, Chavan-klian A, Chesney C, Cleeland C, Coccia PF, Djubegovic B, Garet J, Gilreath JA, Kraut E, Lin WC, Matulovis U, Millensor M, Reinke D, Rosenthal J, Sabbatini P, Schwartz RN, Stein R, Vij R. Cancer and chemotherapy induced anemia [clinical practice guidelines in oncology]. J Natl Compr Canc Netw. 2008;6(6):536-64.
5. Minton O, Stone P, Richardson A, et al. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev. 2008:CD006704.
6. Cella D, Eton DT, Lai J-S, et al. Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy anemia and fatigue scales. J Pain Symptom Manage. 2002;24:547-61.
7. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of live and clinical outcomes. Ann Oncol. 2003;14:511-19.
8. Fallowfield L, Gagnon D, Cella D, et al. Multivariate regression analyses of data from a randomized, double-blind, placebo-controlled study confirmed quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer. 2002;87:1341-53.
9. Hagerty K. Continued regulatory actions affecting the use of erythropoiesis-stimulating agents. J Oncol Pract. 2008;4(6):267-70.
10. Glaspy JA. Erythropoiesis-stimulating agents in oncology. J Natl Compr Canc Netw. 2008;6(6):565-84.
11. European Medicines Agency Document. Doc Ref EMEA/CHMP/333962/2008, Jun 26 2008.
12. Bennett CL, Silver SM, Djulbegovic G, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer associated anemia. J Amer Med Assn. 2008;299(8):914-24.
13. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12 g/dL with erythropoietin vs. above 10 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatinum for cervical cancer. Gynecol Oncol. 2008;108:317-25.
14. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide and lenolidomide-associated thromboembolism among patients with cancer. J Amer Med Assn. 2006;296:2558-60.
15. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombi-nant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter open-label, randomized trial. J Clin Oncol. 2004;22:1301-7.
16. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231-42.
17. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21:627-32.
18. Bastit L, Vanderbroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26(10):1611-18.
19. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol. 2008;26(10):1619-25.
20. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-60.
21. Leyland-Jones B, Semiglozov V, Pawliki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly non anemic patients with metastatic breast cancer receiving first line chemotherapy. A survival study. J Clin Oncol. 2005;23:5960-72.
22. Wright JR, Ung YC, Julian JA, et al. Randomized double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer with disease related anemia. J Clin Oncol. 2007;25:1027-32.
23. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122:394-403.
24. Overgaard J, Hoff C, San Hansen H. Randomized study of the importance of novel erythro-poiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group (DAHANCA 10 [Abstract]). Eur J Cancer Suppl. 2007;5(6):7. Abstract 6LB.
25. Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26: 1040-50.
26. U.S. Food and Drug Administration. Press release: FDA receives new data on risks of anemia drugs consistent with previous data on tumor growth and death. 3 Jan 2008. Available at http://www.fda.gov/lls/topics/NEWS/2008/ NEW01769.html
27. Anonymous. A randomized double-blind placebo-controlled study with subcutaneous recom-binant human erythropoietin in patients with low risk myelodysplastic syndromes: Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol. 1998;103:1070-4.
28. Rothman DJ, McDonald WJ, Berkowitz CD, et al. Professional medical associations and their relationships with industry. JAMA 2009;301(13):1367-72.